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Purpose: Previous studies have suggested that higher circulating 25-hydroxyvitamin D 
[25(OH)D] levels are associated with decreased colorectal cancer (CRC) risk and improved 
survival. However, the influence of vitamin D status on disease progression and patient survival 
remains largely unknown for patients with advanced or metastatic CRC.
Experimental design: We prospectively collected blood samples in 1,041 patients with 
previously untreated advanced or metastatic CRC participating in a randomized phase III clinical 
trial of first-line chemotherapy plus biologic therapy. We examined the association of baseline 
plasma 25(OH)D levels with overall survival (OS) and progression-free survival (PFS). Cox 
proportional hazards models were used to calculate hazard ratios (HRs) and confidence intervals 
(CIs), adjusted for prognostic factors and confounders.
Results: At study entry, 63% of patients were vitamin D deficient (<20 ng/mL) and 31% were 
vitamin D insufficient (20 to <30 ng/mL). Higher 25(OH)D levels were associated with an 
improvement in OS and PFS (Ptrend=0.0009 and 0.03, respectively). Compared to patients in the 
bottom quintile of 25(OH)D (≤10.8 ng/mL), those in the top quintile (≥24.1 ng/mL) had a 
multivariable-adjusted HR of 0.66 (95% CI, 0.53 to 0.83) for OS and 0.81 (95% CI, 0.66 to 1.00) 
for PFS. The improved survival associated with higher 25(OH)D levels was consistent across 
patient subgroups of prognostic patient and tumor characteristics.
Conclusions: In this large cohort of patients with advanced or metastatic CRC, higher plasma 
25(OH)D levels were associated with improved OS and PFS. Clinical trials assessing the benefit of 
vitamin D supplementation in CRC patients are warranted.
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Introduction
Vitamin D deficiency is increasingly prevalent in the United States. A national survey 
showed that only 23% of Americans have serum 25-hydroxyvitamin D [25(OH)D] levels 
≥30 ng/mL, the level required for optimum health (1). Most foods, unless they are fortified, 
are poor sources of vitamin D. Thus, exposure to type B ultraviolet (UV-B) radiation is the 
major determinant of vitamin D status in humans. Over the past decades, skin cancer 
prevention campaigns that recommend avoidance of sun exposure, coupled with more 
daylight hours spent indoors and increasing prevalence of obesity, may have contributed to 
the rising prevalence of vitamin D deficiency, particularly in northern latitudes (2).
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United 
States (3). Among CRC patients, only 39% are diagnosed at an early stage with a 5-year 
survival rate of 90%; the survival rates decline to 71% and 14% for locally advanced and 
metastatic stages, respectively (4). Vitamin D has antineoplastic properties (5), and CRC 
patients are prone to vitamin D deficiency (6–9). Prospective epidemiologic studies 
consistently show an association between higher vitamin D status and improved survival 
among patients with all stages of CRC (8,10–13). However, the influence of vitamin D status 
on cancer progression and survival remains largely unknown for patients with advanced or 
metastatic CRC. We therefore examined the prevalence of vitamin D deficiency and the 
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association between baseline plasma 25(OH)D levels and survival outcome in a large cohort 
of patients with previously untreated advanced or metastatic CRC enrolled in a randomized 
phase III clinical trial of first-line chemotherapy plus biologic therapy.
Methods
Study population
Patients in this study were drawn from the Cancer and Leukemia Group B (CALGB; now a 
part of the Alliance for Clinical Trials in Oncology) and SWOG 80405 (Alliance) trial, 
which was designed in collaboration with the National Cancer Institute to compare various 
combinations of chemotherapy [leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) or 
leucovorin, fluorouracil, and irinotecan (FOLFIRI) per investigator’s choice] with biologic 
therapy as first-line treatment of advanced and metastatic CRC: (1) chemotherapy plus 
cetuximab; (2) chemotherapy plus bevacizumab; and (3) chemotherapy plus cetuximab and 
bevacizumab. Patients were enrolled at centers across the National Clinical Trials Network 
(NCTN) in the United States and Canada. Eligible patients had pathologically confirmed, 
unresectable, locally advanced or metastatic CRC. Patients had to be candidates for either 
mFOLFOX6 or FOLFIRI regimens without known contraindications for bevacizumab or 
cetuximab therapy. Patients were required to have had no previous treatment for advanced or 
metastatic disease but may have received prior adjuvant treatment (≤6 months) that must 
have concluded >12 months before recurrence. Institutional review board approval was 
required at all participating centers and all participating patients provided written informed 
consent. The study was conducted in accordance with the International Ethical Guidelines 
for Biomedical Research Involving Human Subjects (CIOMS).
Full details and results of the treatment trial have been described previously (14). In brief, 
the trial was initiated in September 2005 with a total of 2,326 patients randomized to the 
three treatment arms. The lack of efficacy of EGFR antibodies in KRAS-mutant tumors (15) 
and failure of the chemotherapy and dual antibody combination in other studies (16,17) 
resulted in a pivotal amendment restricting eligibility to patients with confirmed KRAS 
wild-type tumors in November 2008 and closure of the dual antibody arm in September 
2009. Although the final analysis cohort for the treatment trial was comprised of only the 
1,131 KRAS wild-type patients randomized to the bevacizumab-chemotherapy arm or the 
cetuximab-chemotherapy arm, the study population for this vitamin D study was drawn from 
all three arms of CALGB/SWOG 80405 (Alliance). Among the 2,326 patients, 1,041 
provided blood samples at study entry for biomarker research and had 25(OH)D levels 
measured (Supplementary Fig. S1). We compared baseline characteristics of these 1,041 
patients with the entire population as well as the final analysis cohort for the treatment trial, 
and did not detect any appreciable differences (Supplementary Table S1). Moreover, patients 
in both populations experienced similar overall survival (OS) (median=28.8 and 31.2 
months, respectively).
Plasma 25(OH)D assessment
SWOG oversaw specimen biobanking and distribution of samples for correlative research. 
To measure 25(OH)D, plasma samples were sent by overnight delivery to Heartland Assays 
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(Ames, IA) for radioimmunoassay (18). Masked quality control samples were interspersed 
among the samples, and all laboratory personnel were blinded to survival data. The mean 
intra-assay coefficient of variation was 10%, and National Institute of Standards and 
Technology reference ranges (±SDs) were met as follows: 23.3±1.8 ng/mL for concentration 
1, 14.6±1.3 ng/mL for concentration 2, 38.6±2.4 ng/mL for concentration 3, and 33.1±2.6 
ng/mL for concentration 4.
Clinical outcomes
The primary endpoint of OS was calculated from time of study entry to death or last known 
follow-up for those without reported death. The secondary endpoint of progression-free 
survival (PFS) was calculated from study entry to first documented progression or death. 
Patients alive without documented progression were censored for PFS at the most recent 
disease assessment. Disease assessment was done by treating investigators and was not 
blinded.
Covariates
Body mass index (BMI) was calculated from weight and height measured at study entry 
(weight in kilograms divided by square of height in meters). At enrollment, patients were 
given the option of inclusion in the diet and lifestyle companion study. Within the first 
month of enrollment, 774 of the 1,041 patients completed a questionnaire capturing diet and 
lifestyle habits at diagnosis of advanced or metastatic disease, including a validated semi-
quantitative food frequency questionnaire that consisted of 131 food items plus vitamin and 
mineral supplement use. A physical activity score, expressed in metabolic equivalent-hours/
week, was derived by multiplying the time spent on each activity per week by the typical 
energy expenditure for that activity and then summing contributions from all activities. 
Dietary vitamin D and calcium intakes were computed by multiplying the frequency of 
consumption of each food by its nutrient content and summing contributions from all foods.
Patients who consented to be tested for KRAS agreed to submit two archival paraffin-
embedded tumor tissue sections and one histology reference slide or one paraffin-embedded 
tumor block of previously resected primary colorectal tumor and/or a metastatic tumor 
deposit. KRAS and NRAS mutation status was determined by BEAMing (beads, emulsion, 
amplification, magnetics; Hamburg, Germany) technology.
Statistical analyses
Survival curves were generated using the Kaplan–Meier method (19), and statistical 
significance was measured using the log-rank test (20). Cox proportional hazards models 
(21) were used to examine the association of 25(OH)D levels with OS and PFS. The 
assumption of proportional hazards was tested and met by evaluating a time-dependent 
variable, which was the product of 25(OH)D level and time. Hazard ratios (HRs) and 95% 
confidence intervals (CIs) were calculated according to (1) quintile of 25(OH)D, with the 
lowest quintile as the reference group; and (2) clinical category of 25(OH)D (<10, 10 to <20, 
or ≥20 ng/mL), with <10 ng/mL as the reference group. We tested for a linear trend using 
the median value of each quintile as a continuous variable. In multivariable models, we 
included a piori the covariates that are known to be prognostic factors for CRC survival or 
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related to 25(OH)D levels, including age, sex, race, Eastern Cooperative Oncology Group 
(ECOG) performance status, RAS mutation status, prior adjuvant chemotherapy, 
chemotherapy backbone, assigned treatment arm, BMI, physical activity, geographic region 
of residence (as a surrogate for UV-B exposure), and season of blood collection.
We next examined whether the association of 25(OH)D levels with OS and PFS varied 
according to other prognostic factors. Interactions between 25(OH)D and potential effect 
modifiers were assessed by entering in the model the cross product of the 25(OH)D level as 
a continuous variable and the stratification variable, evaluated by the likelihood ratio test.
Data collection was conducted by the Alliance Statistics and Data Center. Data quality was 
ensured by review of data by the Alliance Statistics and Data Center following Alliance 
policies. Statistical analysis was performed based on the study database frozen on January 
18, 2018, using SAS software, version 9.4 (SAS Institute, Cary, NC). All P-values are two 
sided and were considered significant at the 0.05 level.
Results
Among 1,041 patients with advanced or metastatic CRC, the mean age was 59 years 
(standard deviation, 12 years), with 58% males and 42% females. The vast majority of 
patients were white (86%). At study entry, the median plasma 25(OH)D level in the entire 
study population was 17.2 ng/mL (range, 2.2 to 72.7 ng/mL) and the mean was 17.7 ng/mL 
(standard deviation, 7.6 ng/mL); 63% of patients were vitamin D deficient (<20 ng/mL), 
31% were vitamin D insufficient (20 to <30 ng/mL), and only 6% were vitamin D sufficient 
(≥30 ng/mL). We also detected a 17% prevalence of extremely low 25(OH)D levels (<10 ng/
mL).
Baseline characteristics by quintile of 25(OH)D are shown in Table 1. Patients with higher 
25(OH)D levels had a lower BMI, were more likely to be of white race, were more likely to 
possess an ECOG performance status of 0, were more likely to have RAS wild-type tumors 
(defined as wild-type in both KRAS and NRAS), and consumed higher levels of total 
vitamin D and calcium.
The median follow-up time among living patients was 5.6 years (90th percentile: 7.7 years). 
A total of 987 patients (95%) had died or progressed. Survival curves by quintile of 
25(OH)D are shown in Figure 1 (log-rank P comparing extreme quintiles=0.0004 for OS and 
0.02 for PFS). Higher 25(OH)D levels were associated with a significant improvement in OS 
(Ptrend=0.001; Table 2). These results did not change after adjustment for potential 
confounding factors (Ptrend=0.0009). Compared to patients in the bottom quintile of 
25(OH)D (≤10.8 ng/mL), those in the top quintile (≥24.1 ng/mL) had a multivariable-
adjusted HR for OS of 0.66 (95% CI, 0.53 to 0.83), corresponding to an 8-month longer 
median OS time. Similarly, higher plasma 25(OH)D levels were associated with a significant 
improvement in PFS, with patients in the top quintile having a multivariable-adjusted HR for 
PFS of 0.81 (95% CI, 0.66 to 1.00; Ptrend=0.03), compared to those in the bottom quintile. In 
sensitivity analyses, we additionally adjusted for number of metastatic sites and liver 
metastasis, and the association remained similar. In analyses examining survival by clinical 
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category of 25(OH)D, a similar positive association was noted between 25(OH)D levels and 
patient survival (Table 3).
We examined the association of 25(OH)D levels with OS and PFS across strata of other 
prognostic factors. The association of 25(OH)D levels with OS and PFS remained largely 
unchanged across subgroups, including age, sex, ECOG performance status, prior adjuvant 
chemotherapy, chemotherapy backbone, assigned treatment arm, primary tumor location, 
RAS mutation status, BMI, physical activity, total vitamin D intake, geographic region of 
residence, and season of blood collection (all Pinteraction≥0.11; Figure 2).
Discussion
Among 1,041 patients with advanced or metastatic CRC, we found that 63% of patients 
were vitamin D deficient and 31% were vitamin D insufficient at baseline. Higher plasma 
25(OH)D levels were associated with a significant improvement in OS and PFS. The benefit 
associated with higher 25(OH)D levels was consistent across most strata of demographic, 
lifestyle, and pathological characteristics. To our knowledge, this was the largest study of the 
association between circulating 25(OH)D levels and survival among patients with advanced 
or metastatic CRC when it was presented at the Annual Meeting of the American Society of 
Clinical Oncology in 2015 (22).
The high prevalence of vitamin D deficiency among patients with advanced or metastatic 
CRC is consistent with – and indeed more pronounced than – the trend in vitamin D status in 
the general US population. In the National Health and Nutrition Examination Survey 
(NHANES) between 2001 and 2004, the mean serum 25(OH)D level was 24 ng/mL among 
13,369 participants, indicating a remarkable decrease from the third NHANES (1988–1994), 
when the mean 25(OH)D level was 30 ng/mL (1). The major causes of this progressive 
decrease in vitamin D status include avoidance of sun exposure for skin cancer prevention in 
conjunction with increased use of sunscreen, decreased levels of physical activity, increased 
percentage of workforce being indoors, and the rising obesity epidemic in the US 
population. Compared to the general population, our participants with advanced or 
metastatic CRC had particularly low levels of 25(OH)D with a mean of 17.7 ng/mL, which 
was consistent with previous studies (6,7). We noted that patients with RAS mutant tumors 
had lower 25(OH)D levels than those with RAS wild-type tumors. Preclinical studies 
suggest that KRAS mutation could modulate vitamin D activity through the down-regulation 
of vitamin D receptor (VDR) (23) or resistance to growth inhibition by calcitriol 
[1,25(OH)2D] (24,25), the hormonally active form of vitamin D. Although we found no 
interaction between 25(OH)D levels and RAS mutation on patient survival, further research 
is warranted to investigate the underlying mechanisms.
The observed association between 25(OH)D levels and survival among patients with 
advanced or metastatic CRC is consistent with prior findings. We previously reported that 
higher prediagnostic plasma 25(OH)D levels were associated with improved OS in 304 
patients with all stages of CRC from two prospective cohort studies (10). In another study of 
515 metastatic CRC patients nested within the North Central Cancer Treatment Group trial 
N9741, we noted no association between plasma 25(OH)D levels and OS in the entire 
Yuan et al. Page 6













population but a benefit of higher 25(OH)D levels on OS among patients receiving FOLFOX 
(6). Recently, a meta-analysis of 11 studies, including the abovementioned two, with a total 
of 7,718 CRC patients found a robust association of higher circulating 25(OH)D levels with 
improved overall and CRC-specific survival (26). In addition, the promising results of the 
current study led to a randomized double-blind phase II trial, SUNSHINE, of 139 patients 
with KRAS wild-type advanced or metastatic CRC, to test whether vitamin D 
supplementation to raise plasma 25(OH)D levels can improve outcomes in these patients. 
This trial was recently published, showing that patients randomized to high-dose vitamin D 
supplementation (4000 IU/d) had sufficiently increased 25(OH)D levels and improved PFS 
compared to those receiving lose-dose vitamin D supplementation (400 IU/d) (7).
Abundant preclinical evidence supports the hypothesis that vitamin D may possess 
antineoplastic activity against CRC. VDR and 1-α-hydroxylase, which converts 25(OH)D 
into 1,25(OH)2D, are present in colon cancer cells (27–29). The binding of VDR by 
1,25(OH)2D promotes differentiation (30,31), activates apoptotic pathways (32), and inhibits 
angiogenesis (33,34), proliferation (35), and metastasis (36) of colon cancer. In the 
genetically engineered mouse model of intestinal carcinogenesis (APCmin), tumor burden 
was significantly increased by inactivation of the VDR gene (37) and decreased by treatment 
with vitamin D or its synthetic analogue (38). Other mechanisms through which vitamin D 
may influence colorectal carcinogenesis include modulation of cellular immunity and 
systematic inflammation (39,40).
The current study has several strengths. The patient population was large and drawn from a 
rigorously conducted, multicenter NCTN phase III randomized clinical trial. All patients had 
pathologically proven advanced or metastatic CRC at study entry, with standardized 
treatment and follow-up care, as well as regular examinations to prospectively record the 
date and nature of cancer progression. Extensive and detailed information on lifestyle and 
disease characteristics was prospectively collected, so we were able to accurately adjust for 
potential confounders and assess their interactions with 25(OH)D levels on survival.
Nonetheless, several potential limitations warrant discussion. Because 25(OH)D levels were 
only measured once at study entry, the impact of changes in these levels on survival could 
not be studied. It is possible that lower baseline 25(OH)D levels are a surrogate for greater 
burden of cancer, inadequate nutrition, or limited physical activity from illness, all of which 
are associated with worse survival. We adjusted for these factors in multivariable analyses 
and continued to see a significant independent effect of higher vitamin D status on improved 
survival, and more importantly, our SUNSHINE randomized phase II trial (7) supports 
causality in the relationship between vitamin D and CRC survival. Finally, patients who 
enroll on clinical trials may not be representative of the population at large. Although 
CALGB/SWOG 80405 (Alliance) was conducted within the NCTN, which is composed of 
both academic and community hospitals throughout North America, our participants were 
predominantly individuals of European descent, and additional studies in other populations 
are warranted.
In conclusion, we observed a particularly high prevalence of vitamin D deficiency among 
patients with advanced or metastatic CRC. In light of our findings that higher 25(OH)D 
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levels are associated with improved OS and PFS, randomized trials are warranted to assess 
the benefit of vitamin D supplementation in CRC patients. These findings, followed by the 
promising results of our SUNSHINE randomized phase II trial (7), have now paved the way 
for an Alliance-led randomized phase III trial of vitamin D supplementation in combination 
with standard chemotherapy plus biologic therapy among previously untreated metastatic 
CRC patients (SOLARIS, Protocol A021703) to confirm causality. Correlative research 
using biospecimens from these clinical trial cohorts are also warranted to further elucidate 
underlying mechanisms of action.
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Preclinical and epidemiologic evidence indicates that vitamin D has a beneficial effect on 
colorectal cancer (CRC) survival. Among 1,041 patients with advanced or metastatic 
CRC participating in a randomized clinical trial, we observed a particularly high 
prevalence of vitamin D deficiency at baseline. Higher plasma 25-hydroxyvitamin D 
[25(OH)D] levels were associated with a significant improvement in overall and 
progression-free survival, indicating that vitamin D supplementation to raise 25(OH)D 
levels may play a role in treatment of advanced and metastatic CRC. Clinical trials 
assessing the benefit of vitamin D supplementation in CRC patients are warranted.
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Kaplan-Meier curves for (A) overall survival and (B) progression-free survival according to 
quintile of plasma 25-hydroxyvitamin D. Patients in quintiles 2 to 4 were combined for ease 
of graphic viewing.
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Multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for (A) 
overall survival and (B) progression-free survival, comparing the highest to lowest quintile 
of plasma 25-hydroxyvitamin D, across strata of potential effect modifiers. Adjusted for age 
(continuous), sex (female, male), race (white, black, other, unknown), Eastern Cooperative 
Oncology Group (ECOG) performance status (0, 1, 2), prior adjuvant chemotherapy (yes, 
no), chemotherapy backbone [leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6); 
leucovorin, fluorouracil, and irinotecan (FOLFIRI)], assigned treatment arm (bevacizumab, 
cetuximab, bevacizumab + cetuximab), RAS mutation status (wild-type, mutant, unknown), 
body mass index (continuous), physical activity (continuous), season of blood collection 
(summer, fall, winter, spring, unknown), and geographic region of residence (southern US, 
midwestern/western US, northeastern US, Canada, unknown), excluding the stratification 
variable. MET, metabolic equivalent.
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Table 3.
Hazard ratios for overall survival and progression-free survival by clinical category of plasma 25-
hydroxyvitamin D
Plasma 25-hydroxyvitamin D level
<10 ng/mL 10 to <20 ng/mL ≥20 ng/mL
OS
 No. of events/No. of patients 135/152 426/491 332/398
 Median OS (95% CI), months 23 (20–26) 29 (27–31) 31 (27–34)
 Unadjusted HR (95% CI) 1 0.82 (0.67–0.99) 0.72 (0.59–0.88)
 Multivariable-adjusted HR (95% CI)
a 1 0.78 (0.64–0.96) 0.70 (0.56–0.86)
PFS
 No. of events/No. of patients 146/152 466/491 375/398
 Median PFS (95% CI), months 9 (9–11) 10 (9–11) 11 (11–13)
 Unadjusted HR (95% CI) 1 0.88 (0.73–1.06) 0.80 (0.66–0.96)
 Multivariable-adjusted HR (95% CI)
a 1 0.87 (0.71–1.06) 0.81 (0.66–1.00)
Abbreviations: CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
a
Adjusted for age (continuous), sex (female, male), race (white, black, other, unknown), Eastern Cooperative Oncology Group performance status 
(0, 1, 2), prior adjuvant chemotherapy (yes, no), chemotherapy backbone (leucovorin, fluorouracil, and oxaliplatin; leucovorin, fluorouracil, and 
irinotecan), assigned treatment arm (bevacizumab, cetuximab, bevacizumab + cetuximab), RAS mutation status (wild-type, mutant, unknown), 
body mass index (continuous), physical activity (continuous), season of blood collection (summer, fall, winter, spring, unknown), and geographic 
region of residence (southern US, midwestern/western US, northeastern US, Canada, unknown).
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